Evidence map›Paper›PMID 38767710›Full record

ArticleClinical rheumatology2024

Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement.

Jirong Cheng, Yuanhong Peng, Qiurong Wu, Qian Wu, Jing He, Guohua Yuan

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Observational
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jirong Cheng *Department of Rheumatology and Immunology, The Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, China.ORCID http://orcid.org/0009-0000-2735-0658
Yuanhong Peng *Jinan University, Guangzhou, China.
Qiurong WuDepartment of Rheumatology and Immunology, The Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, China.
Qian WuDepartment of Rheumatology and Immunology, The Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, China.
Jing HeDepartment of Rheumatology and Immunology, Peking University People's Hospital, 11 Xizhimen South St., Beijing, 100044, China. hejing@pkuph.edu.cn.
Guohua YuanJinan University, Guangzhou, China. ghyuan1981@139.com.

Funding

Beijing sci-Tech Program Z191100006619114National Key R&D Program of China 2022YFC3602000National Key R&D Program of China 2022YFE0131700National Natural Science Foundation of China 82071813，8227183
6 · The paper itself

Abstract

objectiveTo evaluate the efficacy and safety of telitacicept in SLE patients specifically with hematological involvement.

methodA total of 22 patients with SLE and hematological involvement were included in this study. These patients received telitacicept in addition to standard therapy. We compared their demographic characteristics, clinical manifestations, and laboratory indicators before and after the administration of telitacicept.

resultsA total of 22 patients received telitacicept treatment for a median duration of 10.4 months (ranging from 6 to 19 months). Following telitacicept therapy, significant improvements were observed in various parameters compared to baseline. Specifically, white blood cell count increased from (3.98 ± 1.80) 10

conclusionThe combination of telitacicept and standard treatment demonstrated significant improvements in anemia, as well as increased leukocyte and platelet levels in patients with SLE and hematological involvement. Importantly, the observed adverse events were manageable and controllable. Key Points • Telitacicept effectively improves anemia, clinical outcomes, and increases leukocyte and platelet counts. • Treatment with telitacicept leads to decreased levels of lgG, IgA, anti-dsDNA, and SLEDAI scores, while serum complement C3 and C4 returned to normal. • During the follow-up period there were observed changes in individual parameters, clinical symptoms, and organ involvement, all without significant adverse events.

Indexed as

Lupus Erythematosus, SystemicAdultComplement C3FemaleHemoglobinsHumansLeukocyte CountMaleMiddle AgedPlatelet CountSeverity of Illness IndexTreatment OutcomeYoung AdultComplement C3HemoglobinsHematological involvementLupus erythematosus, systemicTelitacicept

Identifiers

PMID38767710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.